tallysomycin S10b

Tallysomycin S10b is a biosynthetic derivative of the antitumor antibiotic complex tallysomycin B, produced by actinomycetes. It is structurally related to bleomycin and was developed as a potential anticancer agent with similar antineoplastic activity. Unlike bleomycin, its dose-limiting toxicity in animal studies was initially thought to be renal rather than pulmonary, though clinical trials found pulmonary toxicity to be significant. Tallysomycin S10b contains 1,4-diaminobutane as the terminal amine moiety instead of spermidine (as in tallysomycin B). It has demonstrated comparable or greater potency than bleomycin in some preclinical models and shows antibacterial and antifungal activity. Clinical trials have not shown tumor regression but have established a recommended dosing regimen for further study[1][2][5][7]. It induces DNA strand breaks through free radical generation, analogous to other members of the bleomycin family.

Other names

tallysomycin S10bTim S-10b